GLTO
Galecto
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
GLTO Profile
Galecto, Inc.
A clinical stage biotech company focused on novel treatments for fibrosis and cancer
75 State Street, Suite 100, Boston, Massachusetts 02109
--
Galecto, Inc., was incorporated in Delaware in October 2019. The company is a clinical-stage biotechnology company developing novel small molecule therapies designed to target biological processes at the heart of cancer and fibrotic diseases. The company's strategy is to focus on diseases without disease-modifying treatment options and where there is a high degree of unmet medical need. The company is focusing on developing a class of new drugs: small molecule inhibitors of galactose-lectin 3 and lysyl oxidase-like 2, or LOXL 2, which target underlying biology for the treatment of multifactorial diseases such as cancer and fibrotic diseases.